# Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations

> **NCT02298166** · PHASE3 · TERMINATED · sponsor: **University of Ulm** · enrollment: 9 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** chemotherapy (Mitoxantrone, Cytarabine)
- **DRUG:** Placebo
- **DRUG:** Crenolanib
- **OTHER:** Allogeneic stem cell transplantation

## Key facts

- **NCT ID:** NCT02298166
- **Lead sponsor:** University of Ulm
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-11-17
- **Primary completion:** 2020-03-09
- **Final completion:** 2020-03-09
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** The manufacturer Arog Pharmaceuticals Inc has terminated the Agreement Concerning the Support of an Investigator Initiated Trial this became valid on 2020/03/09
- **Last updated:** 2021-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02298166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02298166, "Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02298166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*